Pancreatic Cancer Research

ResearcherShanxi Medical UniversityActive in the last 2 years

Chengfeng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9420-866X; OpenAlex author ID A5017214284. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Construction of a SEMA3 family-based model to predict prognosis and molecular subtypes in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s12672-026-04808-5↗
  2. Delayed gastric emptying risk stratification in patients with pancreatic ductal adenocarcinoma after pancreatoduodenectomy: An international validation cohort … Co-author DOI 10.1002/ueg2.12688↗
  3. Expression, prognostic value and mechanism of SP100 family in pancreatic adenocarcinoma. Last author DOI 10.18632/aging.204811↗
  4. Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma. Last author DOI 10.3389/fmolb.2022.1096679↗
  5. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1172/jci148130↗
  6. Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Progno… Co-author DOI 10.1155/2017/6495867↗
  7. Body mass index does not affect the survival of pancreatic cancer patients. First author DOI 10.3748/wjg.v23.i34.6287↗
  8. Long-term results of intraoperative electron beam radiation therapy for nonmetastatic locally advanced pancreatic cancer: Retrospective cohort study, 7-year ex… Last author DOI 10.1097/md.0000000000004861↗
  9. [Application value of core needle biopsy technique in the pathological diagnosis of locally advanced pancreatic cancer]. Last author PMID 26081211↗
  10. [Total mesopancreas excision in pancreatic cancer-clinical practice and controversy]. Co-author PMID 25142981↗
  11. [Early complications of intra-operative radiotherapy in locally advanced pancreatic cancer]. Last author PMID 25241794↗
  12. [Analysis of the relationship between clinicopathological factors and lymph node matastasis of pancreatic adenocarcinoma]. Co-author DOI 10.3760/cma.j.issn.0253-3766.2013.02.012↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zongting Gu · 3 shared papers, 2022–2025 · strength 0.74
  2. Yongxing Du · 3 shared papers, 2022–2025 · strength 0.74
  3. Yunjie Duan · 3 shared papers, 2022–2025 · strength 0.74
  4. Xiao Guan · 1 shared paper, 2026 · strength 0.39
  5. Xin Jin · 1 shared paper, 2026 · strength 0.39
  6. Xu Che · 5 shared papers, 2014–2021 · strength 0.32
  7. Xiaohao Zheng · 1 shared paper, 2025 · strength 0.30
  8. Jianwei Zhang · 1 shared paper, 2025 · strength 0.30
  9. Jianwei Zhang · 4 shared papers, 2014–2017 · strength 0.22
  10. Yingtai Chen · 4 shared papers, 2014–2017 · strength 0.22
  11. Jie Ma · 2 shared papers, 2017 · strength 0.14
  12. Qinglong Jiang · 2 shared papers, 2016–2017 · strength 0.11
  13. Dongbing Zhao · 2 shared papers, 2016–2017 · strength 0.11
  14. Lusheng Wei · 1 shared paper, 2021 · strength 0.10
  15. Jian Zheng · 1 shared paper, 2021 · strength 0.10
  16. Yanfen Zheng · 1 shared paper, 2021 · strength 0.10
  17. Lingxing Zeng · 1 shared paper, 2021 · strength 0.10
  18. Ying Ye · 1 shared paper, 2021 · strength 0.10
  19. Xudong Huang · 1 shared paper, 2021 · strength 0.10
  20. Guandi Wu · 1 shared paper, 2021 · strength 0.10
  21. Jiachun Su · 1 shared paper, 2021 · strength 0.10
  22. Jialiang Zhang · 1 shared paper, 2021 · strength 0.10
  23. Shaoping Zhang · 1 shared paper, 2021 · strength 0.10
  24. Chen Hsuan Wu · 1 shared paper, 2021 · strength 0.10
  25. Junge Deng · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.